The U.S. pharmaceutical industry emerged mostly unscathed from President Trump’s highly anticipated blueprint to combat rising prescription costs, thanks to the plan’s sidestepping of changes to a Medicare program that benefits the drugmakers.

The firms had grown increasingly concerned the Trump administration would seek to adjust the rates that the federal health insurance program uses to pay for treatments that must be administered by a physician, commonly known as Medicare Part B.